155 related articles for article (PubMed ID: 18949618)
1. Homoharringtonine inhibits the AKT pathway and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.
Meng H; Yang C; Jin J; Zhou Y; Qian W
Leuk Lymphoma; 2008 Oct; 49(10):1954-62. PubMed ID: 18949618
[TBL] [Abstract][Full Text] [Related]
2. PI3K/Akt inhibitor LY294002 potentiates homoharringtonine antimyeloma activity in myeloma cells adhered to stromal cells and in SCID mouse xenograft.
Chen P; Wen X; Wang B; Hou D; Zou H; Yuan Q; Yang H; Xie J; Huang H
Ann Hematol; 2018 May; 97(5):865-875. PubMed ID: 29450644
[TBL] [Abstract][Full Text] [Related]
3. Homoharringtonine enhances bortezomib antimyeloma activity in myeloma cells adhesion to bone marrow stromal cells and in SCID mouse xenografts.
Chen P; Yuan Q; Yang H; Wen X; You P; Hou D; Xie J; Cheng Y; Huang H
Leuk Res; 2017 Jun; 57():119-126. PubMed ID: 28463768
[TBL] [Abstract][Full Text] [Related]
4. Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin.
Kuroda J; Kamitsuji Y; Kimura S; Ashihara E; Kawata E; Nakagawa Y; Takeuichi M; Murotani Y; Yokota A; Tanaka R; Andreeff M; Taniwaki M; Maekawa T
Int J Hematol; 2008 Jun; 87(5):507-515. PubMed ID: 18415656
[TBL] [Abstract][Full Text] [Related]
5. Homoharringtonine induces apoptosis and growth arrest in human myeloma cells.
Lou YJ; Qian WB; Jin J
Leuk Lymphoma; 2007 Jul; 48(7):1400-6. PubMed ID: 17613769
[TBL] [Abstract][Full Text] [Related]
6. PEGylated long-circulating liposomes deliver homoharringtonine to suppress multiple myeloma cancer stem cells.
Li M; Shi F; Fei X; Wu S; Wu D; Pan M; Luo S; Gu N; Dou J
Exp Biol Med (Maywood); 2017 May; 242(9):996-1004. PubMed ID: 28056549
[TBL] [Abstract][Full Text] [Related]
7. Knockdown of c-Met enhances sensitivity to bortezomib in human multiple myeloma U266 cells via inhibiting Akt/mTOR activity.
Que W; Chen J; Chuang M; Jiang D
APMIS; 2012 Mar; 120(3):195-203. PubMed ID: 22339676
[TBL] [Abstract][Full Text] [Related]
8. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells.
Bhardwaj A; Sethi G; Vadhan-Raj S; Bueso-Ramos C; Takada Y; Gaur U; Nair AS; Shishodia S; Aggarwal BB
Blood; 2007 Mar; 109(6):2293-302. PubMed ID: 17164350
[TBL] [Abstract][Full Text] [Related]
9. A novel carbohydrate-based therapeutic GCS-100 overcomes bortezomib resistance and enhances dexamethasone-induced apoptosis in multiple myeloma cells.
Chauhan D; Li G; Podar K; Hideshima T; Neri P; He D; Mitsiades N; Richardson P; Chang Y; Schindler J; Carver B; Anderson KC
Cancer Res; 2005 Sep; 65(18):8350-8. PubMed ID: 16166312
[TBL] [Abstract][Full Text] [Related]
10. [Homoharringtonine combined arsenic trioxide induced apoptosis in human multiple myeloma cell line RPMI 8226: an experimental research].
Zhou XJ; Zhou YH; Chen XH; Qian WB
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Jun; 33(6):834-9. PubMed ID: 23980369
[TBL] [Abstract][Full Text] [Related]
11. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells.
Yang M; Huang J; Pan HZ; Jin J
Int J Mol Med; 2008 Oct; 22(4):489-96. PubMed ID: 18813856
[TBL] [Abstract][Full Text] [Related]
12. Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
Gauduchon J; Seguin A; Marsaud V; Clay D; Renoir JM; Sola B
Int J Cancer; 2008 May; 122(9):2130-41. PubMed ID: 18183592
[TBL] [Abstract][Full Text] [Related]
13. Curcumin circumvents chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against human multiple myeloma in nude mice model.
Sung B; Kunnumakkara AB; Sethi G; Anand P; Guha S; Aggarwal BB
Mol Cancer Ther; 2009 Apr; 8(4):959-70. PubMed ID: 19372569
[TBL] [Abstract][Full Text] [Related]
14. Activation of SHIP via a small molecule agonist kills multiple myeloma cells.
Kennah M; Yau TY; Nodwell M; Krystal G; Andersen RJ; Ong CJ; Mui AL
Exp Hematol; 2009 Nov; 37(11):1274-83. PubMed ID: 19703514
[TBL] [Abstract][Full Text] [Related]
15. Homoharringtonine interacts synergistically with bortezomib in NHL cells through MCL-1 and NOXA-dependent mechanisms.
Nguyen T; Parker R; Zhang Y; Hawkins E; Kmieciak M; Craun W; Grant S
BMC Cancer; 2018 Nov; 18(1):1129. PubMed ID: 30445933
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of phospho-Akt is a major molecular determinant of bortezomib-induced apoptosis in hepatocellular carcinoma cells.
Chen KF; Yeh PY; Yeh KH; Lu YS; Huang SY; Cheng AL
Cancer Res; 2008 Aug; 68(16):6698-707. PubMed ID: 18701494
[TBL] [Abstract][Full Text] [Related]
17. Homoharringtonine Exerts an Antimyeloma Effect by Promoting Excess Parkin-Dependent Mitophagy.
Zhang Y; Huang N; Xu J; Zheng W; Cui X
Drug Des Devel Ther; 2020; 14():4749-4763. PubMed ID: 33177810
[TBL] [Abstract][Full Text] [Related]
18. Homoharringtonine inhibits the progression of hepatocellular carcinoma by suppressing the PI3K/AKT/GSK3β/Slug signaling pathway.
Liu HY; Dong TX; Li ZZ; Li TT; Jiang J; Zhu MW; An TT; Chen YD; Yang XH
Neoplasma; 2021 Sep; 68(5):924-937. PubMed ID: 33998239
[TBL] [Abstract][Full Text] [Related]
19. The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.
David E; Sun SY; Waller EK; Chen J; Khuri FR; Lonial S
Blood; 2005 Dec; 106(13):4322-9. PubMed ID: 16118318
[TBL] [Abstract][Full Text] [Related]
20. Norcantharidin enhances bortezomib-antimyeloma activity in multiple myeloma cells in vitro and in nude mouse xenografts.
Du HF; Yu LJ; Meng YF; Lv HY; Meng J; Song XN; Zhang JQ
Leuk Lymphoma; 2013 Mar; 54(3):607-18. PubMed ID: 22889356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
